NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Forest Laboratories, Inc. (NYSE: FRX)

 
FRX Technical Analysis
5
As on 30th Jun 2014 FRX Share Price closed @ 99.00 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 68.57 & Strong Buy for SHORT-TERM with Stoploss of 93.67 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

FRX Share Price

Open 100.16 Change Price %
High 100.46 1 Day -0.77 -0.77
Low 99.00 1 Week 0.00 0.00
Close 99.00 1 Month 0.00 0.00
Volume 11101530 1 Year 0.00 0.00
52 Week High 145.80 | 52 Week Low 119.37
 
NYSE USA Most Active Stocks
RAI 65.40 -2.23%
EMC 29.05 0.97%
GE 20.16 -1.22%
AKS 4.59 -21.54%
PCS 11.84 -0.92%
AMD 10.98 0.83%
WSH 47.18 -2.86%
JNS 14.17 -0.56%
XLS 24.66 -0.64%
SWY 35.10 -0.11%
 
NYSE USA Top Gainers Stocks
POM 26.93 26.79%
POM 26.93 26.79%
GLF 0.34 25.93%
GLF 0.34 25.93%
TREX 109.45 25.65%
HZO 18.55 22.04%
SSD 55.74 14.62%
TBI 27.10 14.11%
SSTK 38.99 13.84%
KAI 113.60 13.09%
 
NYSE USA Top Losers Stocks
ENL 15.81 -66.25%
ENL 15.81 -66.25%
ENL 15.81 -66.25%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
 
 
FRX
Daily Charts
FRX
Intraday Charts
Whats New @
Bazaartrend
FRX
Free Analysis
 
FRX Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
RESISTANCE100.35
RESISTANCE99.80
SUPPORT98.20
SUPPORT97.65
SUPPORT0.00
SUPPORT0.00
 
FRX Target for Month September
4th UP TARGET0
3rd UP TARGET0
2nd UP TARGET0
1st UP TARGET0
1st DOWN TARGET0
2nd DOWN TARGET0
3rd DOWN TARGET0
4th DOWN TARGET0
 
FRX Weekly Target
4th UP TARGET0.00
3rd UP TARGET0.00
2nd UP TARGET0.00
1st UP TARGET0.00
1st DOWN TARGET0.00
2nd DOWN TARGET0.00
3rd DOWN TARGET0.00
4th DOWN TARGET0.00
 
FRX Target for Year 2020
4th UP TARGET0
3rd UP TARGET0
2nd UP TARGET0
1st UP TARGET0
1st DOWN TARGET0
2nd DOWN TARGET0
3rd DOWN TARGET0
4th DOWN TARGET0
 
 
FRX Other Details
Segment EQ
Market Capital 9041561600.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website >
 
FRX Address
FRX
909 Third Avenue
New York, NY 10022
United States
Phone: 212-421-7850
 
FRX Latest News
 
Your Comments and Response on Forest Laboratories, Inc.
 
FRX Business Profile
Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products in the United States and Europe. The company’s products include Linzess for the treatment of irritable bowel syndrome with constipation or chronic idiopathic constipation; Tudorza Pressair, an antimuscarinic agent to treat bronchospasm associated with chronic obstructive pulmonary disease; Viibryd for the treatment of adults with major depressive disorder (MDD); and Daliresp, a phosphodiesterase-4 enzyme inhibitor to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD. Its products also comprise Teflaro for the treatment of adults with skin and skin structure infections; Bystolic to treat hypertension; Namenda and Namenda XR for the treatment of moderate and severe Alzheimer's disease; Savella to treat fibromyalgia; and Colobreathe, a dry powder inhaler for the treatment of chronic lung infections. In addition, the company develops Levomilnacipran, which is under Phase III clinical trials for the treatment of MDD; Cariprazine that is in Phase III clinical trials to treat acute exacerbation of schizophrenia and acute mania associated with bipolar disorder; ceftazidime/avibactam, which is under Phase III clinical trials for intra-abdominal infections and for complicated urinary tract infections; and Cebranopadol (GRT 6005) that has completed Phase II clinical trials for moderate to severe chronic pain conditions. Forest Laboratories, Inc. sells its products directly to physicians, pharmacies, hospitals, managed care, and other healthcare organizations, as well as through independent distributors. It has collaborative licensing option agreement with Trevena for the development of TRV027 for the treatment of acute decompensated heart failure; and collaboration agreement with Ironwood develop and commercialize Linzess. The company was founded in 1956 and is headquartered in New York, New York. As of May 14, 2014, Forest Laboratories Inc. operates as a subsidiary of Actavis plc.
 
© 2005-2019 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service